Webinar: Effective IMPD Writing. The Quality Part
Effective IMPD writing, including the quality part is a vital document that contains information about an investigational medicinal product and it is an essential part of the Clinical Trial Application (CTA), which is required by competent authorities in EU.
The purpose of this webinar is to share the best practices in the preparation of IMPD in order to meet the expectations of competent authorities and to learn why effective CMC technical writing is crucial for the development of a high quality IMPD.
You will learn about:
1. Regulatory guidelines for the Investigational Medicinal Product Dossier
2. IMPD structure and content
3. Best practices for the preparation of IMPD
- Best practices in IMPD Quality writing;
- Writing style to produce accurate, concise, and clear technical text.
Starting Clinical Trials?
Make use of our expertise to smoothly prepare for clinical studies. Explore your options in a chat with one of our experts.
Who should attend? Professionals from the following fields:
- Product Development
Duration: 40 min.
- Head of the Central Functions for Regulatory Affairs, Ramunė Rūkienė;
- Medical Writer, Eglė Deimantavičiūtė.
Ramunė Rūkienė, MSc
Head of Regulatory Affairs Central Operations
Other content that might interest you:
Regulatory Intelligence is a reliable and invaluable tool when it comes to pharmacovigilance. It's so important because it allows companies to remain up-to-date with the most recent drug safety data and identify new information quickly. What Is Regulatory...
Webinar: How does the conflict between UA & RU impact the pharma industry? Like the rest of the world, the pharmaceutical and biotech industries are beginning to worry about their ability to continue operations. And with good reason. Russia's invasion of Ukraine...
Like the rest of the world, the pharmaceutical and biotech industries are beginning to worry about their ability to continue operations. And, with good reason. Russia's invasion of Ukraine affects millions of people, not just in this Eastern European nation but...